Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03762018 · OUTCOME

Duration of Response (DoR)

BEAT-meso: Bevacizumab and Atezolizumab in Malignant Pleural Mesothelioma · Source last updated 2026-07-22

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
months
Interval / dispersion
95% Confidence Interval
Time frame
From documentation of objective response until the date of first documented progression/relapse or death, up to 52 months.

What was measured

Duration of Response (DoR) is defined as the interval from the date of first documentation of objective response (complete response or partial response, according to the mRECIST v1.1) to the date of first documented progression/relapse or death.

Analysis population: Patients with objective response

Groups in this outcome

Atezolizumab Plus Bevacizumab Plus Chemotherapy

Atezolizumab 1200mg intravenously on day 1 every 3 weeks plus bevacizumab 15mg/kg intravenously on day 1 every 3 weeks plus 4-6 cycles of carboplatin AUC 5 plus pemetrexed 500mg/m\^2 intravenously on day 1 every 3 weeks

Bevacizumab Plus Chemotherapy

Bevacizumab 15mg/kg intravenously on day 1 every 3 weeks plus 4-6 cycles of carboplatin AUC 5 plus pemetrexed 500mg/m\^2 intravenously on day 1 every 3 weeks

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Atezolizumab Plus Bevacizumab Plus Chemotherapy110
Bevacizumab Plus Chemotherapy98

Reported measurements

Source class 1
Values in months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Atezolizumab Plus Bevacizumab Plus Chemotherapy8.2Not reported6.89.7Not reported
Bevacizumab Plus Chemotherapy5.6Not reported4.87.0Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        6.8
        upper Limit
        9.7
        value
        8.2
      2. group Id
        OG001
        lower Limit
        4.8
        upper Limit
        7.0
        value
        5.6
denoms
  1. counts
    1. group Id
      OG000
      value
      110
    2. group Id
      OG001
      value
      98
    units
    Participants
description
Duration of Response (DoR) is defined as the interval from the date of first documentation of objective response (complete response or partial response, according to the mRECIST v1.1) to the date of first documented progression/relapse or death.
dispersion Type
95% Confidence Interval
groups
  1. description
    Atezolizumab 1200mg intravenously on day 1 every 3 weeks plus bevacizumab 15mg/kg intravenously on day 1 every 3 weeks plus 4-6 cycles of carboplatin AUC 5 plus pemetrexed 500mg/m\^2 intravenously on day 1 every 3 weeks
    id
    OG000
    title
    Atezolizumab Plus Bevacizumab Plus Chemotherapy
  2. description
    Bevacizumab 15mg/kg intravenously on day 1 every 3 weeks plus 4-6 cycles of carboplatin AUC 5 plus pemetrexed 500mg/m\^2 intravenously on day 1 every 3 weeks
    id
    OG001
    title
    Bevacizumab Plus Chemotherapy
param Type
MEDIAN
population Description
Patients with objective response
reporting Status
POSTED
time Frame
From documentation of objective response until the date of first documented progression/relapse or death, up to 52 months.
title
Duration of Response (DoR)
type
SECONDARY
unit Of Measure
months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice